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E-mail: lieber00@u.washington.eduWe recently reported on an in vivo hematopoietic stem cell
(HSC) gene therapy approach. It involves the subcutaneous
injections of G-CSF/AMD3100 to mobilize HSCs from the
bone marrow into the peripheral blood stream and the intrave-
nous injection of an integrating helper-dependent adenovirus
vector system. HSCs transduced in the periphery homed back
to the bone marrow, where they persisted long-term. However,
high transgene marking rates found in primitive bone marrow
HSCs were not reflected in peripheral blood cells. Here, we
tested small-molecule drugs to achieve selective mobilization
and transduction of HSCs. We found more efficient GFP
marking in bone marrow HSCs but no increased marking
in the peripheral blood cells. We then used an in vivo HSC
chemo-selection based on a mutant of the O6-methylguanine-
DNA methyltransferase (mgmtP140K) gene that confers resis-
tance to O6-BG/BCNU and should give stably transduced
HSCs a proliferation stimulus and allow for the selective sur-
vival and expansion of progeny cells. Short-term exposure
of G-CSF/AMD3100-mobilized, in vivo-transduced mice to
relatively low selection drug doses resulted in stable GFP
expression in up to 80% of peripheral blood cells. Overall, the
further improvement of our in vivo HSC transduction
approach creates the basis for a simpler HSC gene therapy.
INTRODUCTION
Current hematopoietic stem cell (HSC) gene therapy protocols are
based on the transplantation of ex-vivo-transduced HSCs into
myelo-conditioned recipients. Ex vivo culturing of HSCs limits the
ability to transduce the most primitive stem cells, a limitation that
can result in the loss of transduced cells over time in transplant
recipients. Furthermore, the process of ex vivo HSC manipulation/
transplantation is expensive and must be performed in specialized,
accredited centers, a requirement that severely limits access to
patients with common genetic diseases. To simplify HSC gene ther-
apy, we recently developed an approach for in vivoHSC transduction.52 Molecular Therapy: Methods & Clinical Development Vol. 8 March 2
This is an open access article under the CC BY license (http://creativIt involves subcutaneous injections of granulocyte colony-stimulating
factor (G-CSF)/AMD3100 to mobilize HSCs from the bone marrow
into the peripheral blood stream and the intravenous injection of
an integrating helper-dependent adenovirus (HDAd5/35++) vector
system.1 These vectors target CD46, a receptor that is expressed at
higher levels in HSCs than in more differentiated bone marrow and
blood cells. We demonstrated in transgenic mice expressing human
CD46 (hCD46) in a pattern similar to humans2 and in immunodefi-
cient mice with engrafted human CD34+ cells that HSCs transduced
with HDAd5/35++ in the periphery home back to the bone marrow,
where they persist and stably express the transgene long-term.1 To
confer integration of a GFP transgene cassette, we utilized a hyperac-
tive Sleeping Beauty transposase (SB100x) system3 in the context of a
helper-dependent HDAd5/35++ vector (HDAd-SB) (Figure 1A). In
our previous study,1 at 20 weeks after mobilization and intravenous
injection of a EF1a-promoter-GFP-cassette-containing transposon
vector (HDAd-GFP) and HDAd-SB, we detected GFP marking in
bone marrow lineage(lin)/Sca1+/cKit+ (LSK) cells in the range of
5% and in colony-forming units (CFUs) in the range of 20%. How-
ever, the percentage of GFP-expressing peripheral blood mononu-
clear cells (PBMCs) was on average less than 1% at 20 weeks
post-transduction. This is a shortcoming of our approach because
for most genetic blood disorders to be cured, the transgene product
must be expressed in differentiated peripheral blood cells.
To improve upon this shortcoming, we pursued two different
strategies aimed at increasing the frequency of transgene-expressing018 ª 2017 The Author(s).
ecommons.org/licenses/by/4.0/).
Figure 1. GFP Expression in HSCs and Lineage-Positive Cells in Bone Marrow, Spleen, and PBMCs
(A) Integrating HDAd5/35++ vectors. The transposon vector (HDAd-GFP) carries the GFP expression cassette that is flanked by inverted transposon repeats (IR) and FRT
sites. PA, polyadenylation signal. The second vector (HDAd-SB) provides both Flpe recombinase and the SB100x transposase in trans. Both vectors are helper-dependent
(HDAd) adenovirus vectors containing the CD46 affinity-enhanced Ad35++ fiber knob and the Ad35 fiber shaft.28 Upon co-infection of both vectors, Flpe mediates the
circularization of the transposon through FRT sites. SB100x then randomly integrates the transposon into the host genome through interaction with the IRs. (B) In vivo
transduction of mobilized hCD46tg mice. HSCs were mobilized by s.c. injection of human recombinant G-CSF for 4 days followed by an s.c. injection of AMD3100. 30 and
(legend continued on next page)
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Molecular Therapy: Methods & Clinical Developmentperipheral blood cells. The first approach is based on the assumption
that G-CSF/AMD3100 mobilization with subsequent HDAd5/35++
in vivo transduction does not allow for the transduction of a
sufficiently high number of HSCs. So far, we have used G-CSF and
AMD3100 for HSC mobilization because this approach is broadly
used for HSC collection.4 G-CSF stimulates proliferation of cells in
bone marrow and spleen and results in mobilization of not only
HSCs but also less primitive progenitors into the peripheral blood
circulation, leading to a general increase in white blood cells, i.e.,
targets for HDAd5/35++ transduction. This “sponge” effect reduces
the effective vector dose capable of transducing HSCs. Therefore, we
evaluated alternative HSC mobilization agents in hCD46 transgenic
mice. HSC mobilization can be achieved by interfering with either
(1) a4b1 (VLA) and a9b1 integrins binding to vascular cell adhesion
molecule 1 (VCAM1) or (2) interactions between the chemokine re-
ceptor CXCR4 and its ligand SDF-1. AMD3100, a synthetic small-
molecule CXCR4 antagonist, leads to more rapid mobilization of
HSCs than does G-CSF5–7 and causes mobilization solely through
disruption of the SDF-1-CXCR4 axis. Other small-molecule drugs
that act by mechanisms different from AMD3100 are BIO5192
and BOP (N-(benzenesulfonyl)-L-prolyl-L-O-(1-pyrrolidinylcar-
bonyl)tyrosine. BIO5192 is a small-molecule VLA-4 inhibitor.8 BOP
is a small molecule targeting a9b1/a4b1 integrins.
9
The second approach is based on our previous conclusion that in vivo-
transduced HSCs are, per se, capable of differentiating. For example,
bone marrow GFP+ mononuclear cells harvested at 16 weeks after
in vivo transduction repopulated all peripheral blood cell lineages
after transplantation into lethally irradiated recipients.1 To stimulate
cell division of GFP+ HSCs and give their progeny a selective advan-
tage, we plan to use a drug-resistance gene followed by application of
the appropriate cytotoxic agent.10 Upon transplantation of lentivirus
vector transduced HSCs, in vivo chemo-selection has been success-
fully demonstrated using a P140K mutant version of the human
O6-methylguanine-DNA methyltransferase (mgmt) gene that
confers resistance to relatively low-doses of methylating agents
(e.g., O6-benzylguanine [O6-BG] plus bis-chloroethylnitrosourea
(BCNU) or temozolomide.11–13 MGMTP140K expression in HSCs
allowed for stable multi-lineage in vivo selection in mice, dogs,
non-human primates, and humans.11,14,15 Here, we incorporated a
mgmtP140K gene into the HDAd-GFP vector and assessed GFP
marking in in vivo-transduced hCD46 transgenic mice.
RESULTS
Discrepancy in Transgene Marking in Bone Marrow HSCs and
Differentiated Peripheral Blood Cells
We transduced G-CSF/AMD3100 mobilized hCD46tg mice with
HDAd-GFP + HDAd-SB (Figures 1A and 1B). We periodically60 min after AMD3100 injection, animals were intravenously injected with a 1:1 mixture
week 30 after HDAd-GFP + HDAd-SB injection. (C) Bone marrow at week 30 after HDA
(MNCs), lineage-positive cells (CD3+, CD19+, Gr-1+, and Ter119+), and HSCs (LSK cells
and lineage-positive cells at week 30. (E) Percentage of GFP+ cells in total PBMCsmeasu
animal. N = 10. (F) Percentage of GFP+ cells in peripheral blood lineages.
54 Molecular Therapy: Methods & Clinical Development Vol. 8 March 2measured GFP expression in PBMCs and sacrificed the animals
30 weeks later to analyze GFP expression in bone marrow and
spleen. In bone marrow, GFP marking in LSK cells, a subfraction
that is considered to be enriched for HSCs, was 5% (Figure 1C).
Average GFP marking rates in the range of 10%–18% were found
in bone marrow CD3+ and CD19+ cells as well as in Ter119+ cells.
The percentage of GFP-expressing pro-granulocytes (Gr-1+) in
bone marrow was 3%. In the spleen, a secondary hematopoietic
organ to which mobilized HSCs can return,1 we found GFP
marking in 10% of CD3+ and Gr-1+ cells (Figure 1D). Around
30% of CD19+ cells in the spleen expressed GFP. In contrast to
marking rates in bone marrow, GFP expression in PBMCs at
30 weeks was less than 1% in all animals (Figure 1E). Looking at
the kinetics of the percentage of GFP+ PBMCs, the first 2 weeks
show GFP marking in 2%–6% of PBMCs which is in agreement
with our previous study,1 and most likely originates from direct
transduction of circulating PBMCs in the peripheral blood after
intravenous injection of HDAd-GFP + HDAd-SB. The slow decline
of GFP+ PBMCs by week 10 could be the results of natural
turnover of transduced cells. Within transduced PBMCs, CD3+
T cells represented the largest fraction (up to 15% at week 2)
(Figure 1F).
Approach 1: More Efficient In Vivo Transduction of HSCs
through Selective HSC Mobilization Agents
We compared the mobilization efficiency of different agents based on
white blood cell numbers and HSCs in peripheral blood at 1 hr after
drug injection. The goal of this study was to find an approach that
would result in more selective and/or efficient HSC mobilization.
As expected, G-CSF alone and all combinations that contained
G-CSF resulted in high leukocytosis with particularly strong increases
(>15-fold) in neutrophil and eosinophil numbers (Figure 2A).
AMD3100, BIO5192, and BOP alone or in combination increased
white blood cells counts only between 2- and 5-fold, with BOP
triggering the least leukocytosis.
Hematopoietic progenitor numbers in the peripheral blood were
first measured by a functional HSC assay, i.e., the ability to form
multi-lineage progenitor colonies. Peripheral blood was collected
1 hr after the last drug injection and white blood cells were plated
for CFU assays (Figure 2B). Overall, G-CSF (alone and in combi-
nation) mobilized CFU more efficiently than settings without
G-CSF (p < 0.05 compared to control). There was a trend that
the addition of BOP or BIO5192 to G-CSF/AMD3100 increased
the mobilization efficacy but the difference was not significant
(p = 0.061 and p = 0.07). The addition of heparin to G-CSF/
AMD3100 did not increase the number of mobilized CFU and
increased spontaneous bleeding. AMD3100 and BOP alone hadof HDAd-GFP + HDAd-SB (2 injections, each 4  1010 vp). Mice were sacrificed at
d-GFP injection. Shown is the percentage of GFP+ cells in total mononuclear cells
). Each symbol is an individual animal. (D) Spleen. Percentage of GFP+ cells in MNCs
red at the indicated time points after in vivoHDAd injection. Each line is an individual
018
Figure 2. Effect of Different Mobilization Drugs on
White Blood Cell Counts and Colony-Forming Cells
in Peripheral Blood 1 hr after the Last Drug Injection
(A) Peripheral white blood cell counts after mobilization.
G-CSF was given s.c. daily for 4 days. For combinations
with G-CSF, drugs were given at day 5. The following
doses were administered: G-CSF (5 mg/mouse, s.c.),
AMD3100 (5 mg/kg, s.c.), BIO5192 (1 mg/kg, i.v.), BOP
(10mg/kg, s.c.), and heparin (100 units, i.p., together with
AMD3100). Peripheral blood samples were collected 1 hr
after the last drug injection. Shown is the fold increase in
white blood cells over pre-treatment levels. N = 3 animals.
WBC, white blood cells; NE, neutrophils; LY, lympho-
cytes; MO, monocytes; EO, eosinophils. (B) Mobilization
of HSCs based on the number of progenitor colony-
forming cells (CFCs) in 100 mL of blood. Blood samples
were treated with red cell lysis buffer, and all leukocytes
were plated. Colonies were counted 12 days later. Each
symbol is one animal. “Control” refers to untreated
animals.
www.moleculartherapy.orgonly marginal effects on peripheral blood CFU numbers. However,
BIO5192 and the combinations of AMD3100/BIO5192 and
AMD3100/BOP resulted in some degree of HSC mobilization
(p < 0.02 for all three). The mobilization effect of AMD3100
alone was also analyzed by flow cytometry for the LSK cell pheno-
type of HSCs (Figure S1). A single injection of AMD3100 did not
increase the percentage of LSK cells in the peripheral blood at 1
and 3 hr after injection, while G-CSF alone did. We did not
test a recently published approach that involved a continuous
infusion of AMD3100 over 2 weeks and resulted in efficient HSC
mobilization.7
Because of leukocytosis associated with G-CSF, further studies have
focused on AMD3100, BIO5192, and BOP alone compared to the
standard regimen.Molecular Therapy: MethodsGFP Marking at 8 Weeks after HDAd-GFP +
HDAd-SB IV Injection of Mice that Were Mobi-
lized with AMD3100, BIO5192, and/or BOP. At
week 8 after in vivo transduction, the compo-
sition of lin+ cells in bone marrow, spleen,
and blood was similar to non-mobilized
animals (Figure S2). In bone marrow,
AMD3100 and BIO5192 mobilization alone
or in combination resulted in 50% GFP+
mononuclear cells (MNC) (p < 0.01 compared
to G-CSF/AMD3100) (Figure 3A). GFP
expression in BOP-only mobilized mice was
comparable to the G-CSF/AMD3100 setting.
A similar trend was seen for bone marrow
LSK (Figure 3B) and lin+ cells (Figure S3).
In the spleen, AMD3100 or BIO5192 mobi-
lized animals also had higher GFP marking
(Figure S4). Interestingly, the combination of
AMD3100 and BIO5192 was less efficientsuggesting that this drug combination either interfered with the
expansion of directly transduced splenic cells, the return of
mobilized cells to the spleen, or the influx of modified, BM-derived
cells.
Despite the high marking rates obtained with AMD3100 and
BIO5192 in bone marrow and spleen, which indicate more effi-
cient/selective transduction of potential HSCs and progenitors in
the periphery and/or return to hematopoietic tissues, the percentage
of GFP+ PBMCs was below 1.5% for all mobilization settings (Fig-
ure 3C). Moreover, we found that GFP marking seen at week 8 in
AMD3100 and BIO5192 mobilized animals originated from episomal
vectors and was lost once proliferation was triggered in transduced
cells either in CFU or in transplantation assays (Figures 3D–3F). In
colony assays, the frequency of colony formation from plated bone& Clinical Development Vol. 8 March 2018 55
Figure 3. GFP Analysis at 8 Weeks after In Vivo
Transduction with HDAd-GFP and HDAd-SB and
Different Mobilization Regimens
(A–F) hCD46tg mice were mobilized with the indicated
agents and i.v. injected with HDAd-GFP + HDAd-SB.
(Notably, the vector dose [2 times, 2 1010 vp] was half of
that used in our previous studies1 and in the studies
shown in Figure 1.) Mice were sacrificed at 8 weeks after
injection, and bone marrow cells, splenocytes, and
PBMCs were harvested. (A) GFP expression in total
bone marrow mononuclear cells (MNCs). (B) Percentage
of GFP+ cells in LSK cells. (C) Percentage of GFP+
PBMCs. (D) Colony assay. Bone marrow MNCs were
depleted for lineage-positive cells, sorted for GFP+ cells,
and plated for progenitor colonies assays. Shown is the
percentage of GFP+ colonies that formed after 14 days.
(E) HDAd-GFP vector DNA copies in pooled colonies.
qPCR with primers specific to the GFP cassette using
genomic DNA from pooled colonies derived from
plated lin/GFP+ cells. Each symbol is the result of pooled
colonies from a given animal. (F) Transplantation assay.
Bone marrow cells harvested from in vivo-transduced
hCD46 transgenic mice were transplanted into C57BL/6
mice. Shown is the percentage of GFP+ cells in hCD46+
PBMCs at week 8 after transplantation. *p < 0.05.
Molecular Therapy: Methods & Clinical Developmentmarrow lin/GFP+ cells was comparable for all groups (Figure S5).
However, although all the plated cells were GFP+, GFP+ colonies
were observed only in G-CSF/AMD3100-mobilizedmice (Figure 3D).
To test whether this is due to failure of vector integration and subse-
quent loss of episomal vector DNA during proliferation, we measured
vector DNA copy numbers by qPCR with GFP-specific primers in
pooled colonies (Figure 3E). The analysis demonstrated the absence
of vector DNA in colonies from BIO5192-, AMD3100-, and BOP-
treated mice. In contrast, the vector DNA signal correlated with
GFP expression in pooled colonies from G-CSF/AMD3100-mobi-
lized mice. Notably the vector copy number measured in lin/GFP+
cells before plating was comparable in all settings (1.3 copies
per cell). The lack of detectable integration in AMD3100- or
BIO5192-mobilized, in vivo-transduced animals was also evident in
transplantation studies, where bone marrow cells from in vivo-56 Molecular Therapy: Methods & Clinical Development Vol. 8 March 2018transduced hCD46tg mice were transplanted
into C57BL/6 mice. Engraftment was compara-
ble for all groups (95%) (Figure S6). However,
only mice mobilized with G-CSF/AMD3100
showed GFP-expressing PBMCs (Figure 3F).
This indicates that although 40% of bone
marrowMNCs expressed GFP in the transplant,
GFP expression was lost after engraftment and
differentiation of transduced HSCs.
In summary, AMD3100 and BIO5192 mobiliza-
tion in combination with HDAd vector injection
allows for efficient transient GFP marking in
bone marrow MNCs, including LSK cells atweek 8. This supports our hypothesis that more selective mobilization
by these drugs increases the transduction of certain bone marrow
subsets. However, our data also indicate that SB100x-mediated trans-
poson integration requires the effects of G-CSF on mobilized cells.
With regard to increasing GFP marking in PBMCs, our studies with
AMD3100, BIO5192 andBOP failed to achieve this at a level that would
be therapeuticallymeaningful.All subsequent in vivoHSC transduction
studies were therefore performed with G-CSF/AMD3100 mobilized
hCD46tg mice.
Approach 2: Trigger Cell Cycling in Quiescent GFP+ HSCs and
Provide Proliferative Advantage to Transduced HSC Progeny in
Bone Marrow
One potential reason for the low transgene marking rates in the
periphery could be that most GFP+ HSCs in bone marrow are
Figure 4. Comparison of GFPMarking in BoneMarrow, Spleen, and PBMCs before the Start of 5-FU Treatment (Week 20 after In Vivo Transduction) and after
10 Weeks of Weekly 5-FU Treatment
(A–C) G-CSF/AMD3100-mobilized mice were transduced with HDAd-GFP + HDAd-SB as described in Figure 1. Mice were sacrificed at week 30 after HDAd injection after
10 weeks of 5-FU treatment (40mg/kg, weekly, IP). Bonemarrow (BM). Shown is the percentage of GFP+ cells in total mononuclear cells (A), T cells, B cells, andmyeloid cells
(B), and HSC LSK cells (C). (D and E) Spleen. Shown is the percentage of GFP+ cells in total spleen MNCs (D) and lineage-positive cells (E). (F and G) Percentage of GFP+ cells
in PBMCs. Shown is the percentage of GFP+ cells in total PBMC (F) and lineage-positive cells (G). *p < 0.05.
www.moleculartherapy.orgquiescent. The chemotherapy drug 5-fluorouracil (5-FU) is used to
enrich bone marrow cells for HSCs by triggering HSCs prolifera-
tion.16 Based on the kinetics of loss of GFP marking in PBMCs
(see Figure 1E), we decided to start 5-FU treatment at week 20 after
in vivo transduction, when initially transduced PBMCs had nearly
disappeared from the periphery. 5-FU injections were continued
weekly for 10 weeks. The cyto-depleting effect of 5-FU on lin+ cells
in bone marrow, spleen, and PBMCs was observed based on the
decline in the percentage of CD19+ cells in mononuclear cells
(MNCs) (Figure S7). We then compared GFP marking before the
start of 5-FU treatment (week 20) with that at week 30 (Figure 4).
In bone marrow, upon 5-FU treatment, the percentage of GFP+ cellsMolecusignificantly increased in total MNCs, CD3+, and CD19+ lineage
cells, while it remained unchanged in Gr-1+ and LSK cells (Fig-
ure 4A–4C). 5-FU treatment did not significantly change GFP
marking in the spleen, in total MNCs, or in lin+ cells and remained
in the range of 10%–20% (Figures 4D and 4E). As a result of
5-FU treatment, GFP expression became detectable in PBMCs
and was in the range of 3% (Figure 4F). Marking increased in
all three peripheral blood cell lineages analyzed (Figure 4G). These
results support our hypothesis that forcing bone marrow GFP+
HSCs to proliferate stimulates their differentiation and exit from
the bone marrow and increases transgene marking in peripheral
blood cells.lar Therapy: Methods & Clinical Development Vol. 8 March 2018 57
Figure 5. In Vivo Selection of In Vivo-Transduced HSCs
(A) Vector design. ThemgmtP140K gene is linked to the GFP gene through a self-cleaving picornavirus 2A peptide. Both genes are under the control of the EF1a promoter. PA,
poly-adenylation signal. The transgene cassette is flanked by inverted repeats (IR), which are recognized by the SB100x transposase, and frt sites, which are recognized by
the Flp recombinase. (B) Treatment regimen. hCD46tg mice weremobilized and i.v. injected with HDAd-mgmt/GFP + HDAd-SB (2 times each, 4 1010 vp of a 1:1 mixture of
both viruses). 4 weeks later, PBMCswere harvested before O6-BG/BCNU treatment was started (time point “PBMC [t1]”). This cycle was repeated every 2 weeks for a total of
3 times. With each cycle, the BCNU concentration was increased from 2.5 mg/kg to 7.5 mg/kg and 10 mg/kg. GFP marking was followed until week 18, when animals were
(legend continued on next page)
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www.moleculartherapy.orgTreatment with 5-FU over extended time periods to increase gene
marking in PBMCs is not possible in patients because of potential
immunosuppressive side effects. We therefore evaluated the
mgmtP140K in vivo selection approach, which requires only short-
term exposure to O6-BG/BCNU at doses neither immunosuppressive
nor myeloablative.17 We expected that this would give GFP+ HSCs a
proliferation stimulus and support the selective survival and expan-
sion of progeny cells. For in vivo selection, we modified our HDAd-
GFP transposon vector by linking the mgmtP140K gene to the GFP
gene via a self-cleaving picornavirus 2A peptide (Figure 5A). We first
showed in vitro that the corresponding HDAd5/35++ vector
(HDAd-mgmt/GFP) conferred resistance to O6-BG/BCNU (Fig-
ure S8). We then tested a combined in vivoHSC transduction/in vivo
HSC selection approach in hCD46tg mice (Figure 5B). Animals were
mobilized with G-CSF/AMD3100 and intravenously injected with
HDAd-mgmt/GFP plus HDAd-SB. GFP expression in PBMCs at
6 weeks after transduction (before the first O6-BG/BCNU cycle)
was 1.2 (±0.4)% (Figure 5C, time point “t1”). In two animals sacrificed
at this time point, 5.3 and 6.1% of bone marrow LSK cells expressed
GFP. This is in the range published previously.1 In the remaining
mice,6 weeks after in vivo transduction, three drug treatment cycles
(with 30 mg/kg O6-BG and increasing BCNU doses) were given at
2-week intervals (Figure 5B). The control group was transduced
in vivo but did not receive O6-BG/BCNU. In this group, the percent-
age of GFP+ PBMCs was less than 1% (Figure 5C, left panel). In the
group that received in vivo selection drugs, the percentage of GFP+
PBMCs started to increase after the second treatment and reached
on average of 35% GFP+ PBMCs 4 weeks after the last drug injection
(Figure 5C, right panel). At week 18 after in vivo transduction (week 8
after the last drug treatment), on average 25% of PBMCs expressed
GFP. At this time point, the average percentage of GFP+ MNCs in
mice was 28% in bone marrow and 20% in spleen and PBMCs (Fig-
ure 5D). About 45% of bone marrow LSK cells were GFP+, indicating
that transduced LSK cells had also expanded (Figure 5D). In colony
assays with plated bone marrow lin cells, 30% of colonies were
GFP+ (Figure 5E). Analysis of GFP marking in CD3, CD19, Gr-1,
and Ter119 lin+ cells in bone marrow, spleen and blood showed
comparable levels in the range of 10%–40% (Figure 5F). This suggests
transduction of primitive HSCs with our integrating HDAd-mgmt/
GFP vector and multi-lineage expansion. In mice that did not receive
O6-BG/BCNU the percentage of stably transduced lin cells in bone
marrow ranged from 2% to 5%, a finding that is in agreement with our
previous study (Figure S9; data not shown).
To assess side effects of O6-BG/BCNU on hematopoiesis and differ-
entiated blood cells, we analyzed the cellular composition of bone
marrow, spleen, and blood at week 18 after in vivo transduction (Fig-
ure S10A). Compared to untreated control mice (Figure S10B),sacrificed for GFP analysis in other tissues. (C) Percentage of GFP+ PBMCs in mice wit
treatment is indicated by vertical red arrows. The PBMCcollection time points (“PBMC [t1
and LSK cells in bone marrow (BM), splenic MNCs, and PBMCs (D). GFP+ colonies. Tot
12 days later. Each symbol is the average GFP+ colony number for individual mice. The
in vivo selection (E). GFP+ cells in CD3, CD19, Gr-1, and Ter119 lineage-positive cells
Molecuno remarkable differences were found. We also analyzed the acute
effect of O6-BG/BCNU. In the peripheral blood, a significant decrease
in total white blood cell, neutrophil, lymphocyte, and platelet counts
occurred between days 7 and 10 after drug injection at BCNU doses
greater than 5 mg/kg (Figure S11). Blood cell counts were restored to
physiological levels by day 14 post-drug injection. In bone marrow, at
day 3 after O6-BG/BCNU (10 mg/kg) treatment, the percentage of
Gr-1+ cells was 50% of levels seen in untreated mice (Figure S12).
Furthermore, we observed an increase in CD3+, CD19+, and
Ter119+ cells at day 3. Cell composition in bone marrow at week 4
after O6-BG/BCNU treatment was comparable to untreated animals.
This indicates the absence of a major cyto-depleting effect caused by
10 mg/kg BCNU in bone marrow.
To further confirm that our combined HSC in vivo transduction/
selection approach resulted in genetic modification of primitive
HSCs, we performed a transplantation/repopulation study. Lineage
bone marrow cells from hCD46tg mice collected at week 18 after
in vivo transduction/selection were used for transplantation into
lethally irradiated C57BL/6 mice. The percentage of GFP+ cells in
the lin cell transplant (pooled from 3 mice) was 40%. Analysis of
hCD46 expression on PBMCs at weeks 4, 8, and 12 after transplanta-
tion showed engraftment rates of >90% in all recipients. The percent-
age of GFP+/hCD46+ cells was stable and on average 15% (Figure 6A).
In bone marrow, GFP marking at week 12 was also 12% in LSK
cells, lin and (total) lin+ cells (Figure 6B). A comparable marking
rate was seen in Gr-1+ and Ter119+ cells in bone marrow, spleen,
and PBMCs (Figure 6C); however, variations between animals in
GFP+ CD3+ and CD19+ cells were larger. This could imply that our
vector system more efficiently transduced common myeloid progen-
itors than common lymphoid progenitors. GFP+ cells were also
observed in the brain (Figure 6D), lung, liver, and kidney (not shown)
most likely originating from GFP+ HSCs. Bone marrow lin cells
from recipients gave rise to 10% GFP+ colonies. GFP+ colonies
included CFU-GEMM, CFU-G, BFU-E, and CFU-E expressing
GFP (Figure 6E).
To further increase transgene marking in PBMCs, we performed a
study with two additional cycles of drug treatment (Figure 7A).
Because we did not observe a cyto-depleting effect with BCNU doses
below 5 mg/kg (see Figure S11), we started the in vivo selection pro-
cess at a dose of 7.5 mg/kg followed by three doses of O6-BG 10mg/kg
BCNU 2 weeks apart. 2 weeks after the last drug injection, GFP
marking in PBMCs reached >80% and remained stable (Figure 7B).
At the last time point analyzed (t5), 12 weeks after the last drug injec-
tion, GFP expression was seen on average in 40% CD3+, 40% CD19+,
70% Gr-1+, and 70% Ter119+ of bone marrow lineage cells
and in 50% of LSK cells. Overall, our second in vivo HSChout O6-BG/BCNU treatment (left panel) and with drug (right panel). O6-BG/BCNU
] to PBMC [t6]” are shown in B). (D–F)Week 18 analyses. Percentage of GFP+MNCs
al bone marrow lin cells were plated, and GFP expression in colonies was analyzed
total number of colonies that developed was comparable for mice with and without
in bone marrow, spleen, and PBMCs (F).
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Figure 6. Analysis of GFP Marking in Secondary Recipients
(A–E) Bone marrow cells from mice shown in Figure 5 were harvested at week 18 after in vivo transduction of hCD46tg mice, depleted for lineage-positive cells, and
transplanted into lethally irradiated C57BL/6 mice. (A) Flow cytometry of PBMCs at weeks 4, 8, and 12 after transplantation in four recipient mice. The right panel shows a
typical analysis. The vertical axis shows staining for hCD46, and the horizontal axis shows GFP staining. (B) GFP flow analysis of bone marrow LSK, lineage-positive, and
lineage-negative cells in recipients 8 weeks after transplantation. (C) Analysis of GFP expression in bone marrow, spleen, and peripheral blood T-, B-, myeloid, and erythroid
lineage-positive cells. (D) GFP immunofluorescence of brain tissue sections from recipients. GFP+ resemble microglia. Nuclei are stained with DAPI (blue). The scale bar
represents 50 mm. (E) GFP expression in progenitor colonies. Examples for GFP+ burst-forming units-erythroid (BFU-E), colony-forming units of erythroid progenitors
(CFU-E), granulocyte progenitors (CFU-G), granulocyte/macrophage progenitors (CFU-GM), and multi-potential progenitor cells CFU-GEMM (granulocyte, erythrocyte,
monocyte, and megakaryocyte) are shown. Scale bar represents 500 mm.
Molecular Therapy: Methods & Clinical Developmenttransduction/selection study illustrates the power of the approach for
reaching high transgene marking levels in peripheral blood cells.
Notably, compared to previous studies with the mgmt in vivo selec-
tion system, our approach does not require the isolation of HSCs
and subsequent transplantation.60 Molecular Therapy: Methods & Clinical Development Vol. 8 March 2DISCUSSION
Current protocols for HSC gene therapy, involving the transplan-
tation of ex vivo lentivirus vector-transduced HSCs into myelo-
ablated recipients, are complex, expensive, and therefore difficult
to perform in countries with limited resources. We developed a018
Figure 7. In Vivo Transduction in Combination with
Additional Rounds of Drug Selection and
Subsequent Immunosuppression
(A) Treatment regimen. hCD46tg mice were mobilized
and i.v. injected with HDAd-mgmt/GFP + HDAd-SB
(2 times each, 2  1010 vp of a 1:1 mixture of both
viruses). 8 weeks later, in vivo selection was started with a
dose of 30 mg/kg O6-BG + 7.5 mg/kg BCNU, followed by
three rounds of O6-BG + 10mg/kg BCNU cycles 2 weeks
apart. Time points of PBMC collection are indicated. (B)
Percentage of GFP+ PBMCs at the time points indicated
in (A). (C) Analysis of GFP expression in bone marrow LSK
and lineage-positive cells at time point “t5.”
www.moleculartherapy.orgsimplified approach for in vivo HSC gene therapy that does
not require myeloablation and HSC transplantation. In our
previous study, we have shown that this approach was safe and
resulted in efficient, long-term transgene expression in primitive
HSCs. While we found high GFP marking rates in bone marrow
HSCs, the frequency of GFP-expressing PBMCs was below 1%
and did not increase over time. It is possible that even this low
transgene marking rate is sufficient in diseases in which gene cor-
rected HSC/progeny have a proliferative advantage over non-trans-
duced cells such as X-linked SCID,18 ADA-SCID,19 and Fanconi
anemia.20 However, low transgene marking in differentiated
peripheral blood cells represents a major limitation of our
approach for gene therapy of common genetic diseases, such as
hemoglobinopathies, which require the correction of the majority
of target cells.
We developed two (non-exclusive) hypotheses for the low transgene
marking in peripheral blood cells: (1) the number of GFP+ HSCs
that are transduced in the periphery and return to the bone marrow
is insufficient, and (2) the majority of GFP+ HSCs in bone marrow are
quiescent not contributing to downstream differentiation.
Our first hypothesis that increasing the percentage of transduced
HSCs in bone marrow by using more selective mobilization drugs
would be reflected in increased gene marking in peripheral blood
cells did not prove to be correct. We believe however that our
data are of interest for a better understanding of our in vivo trans-
duction approach and of the fate of HSCs after mobilization with
different drugs: (1) G-SCF alone and in combination triggered
pronounced leukocytosis; (2) our in vivo HSC marking approach
indicates that AMD3100 and BIO5192 results in more efficient
in vivo transduction of HSCs/progenitors that return to the bone
marrow; (3) at week 8 after in vivo transduction, HDAd genomes
can still exist in episomal form in HSCs; and (4) SB100x-mediated
integration requires an effect triggered by G-CSF. The latter needs
to be studied in the future.Molecular Therapy: MethodsThe second hypothesis that GFP+ HSCs in bone
marrow are dormant and need to be pushed
into cycling is supported by our studies with
5-FU and the mgmt in vivo selection system.Five rounds of treatment resulted in >80% of stable PBMC marking
rates in all lineages, including erythroid cells. Furthermore, our data
indicate the transduction of primitive, long-term persisting HSC
that survive in vivo selection and drive the repopulation of the
hematopoietic system after transplantation into lethally irradiated
recipients. That the pool of GFP+ HSCs is maintained suggests that
the in vivo selection approach stimulates assymetric cell division in
GFP+ HSCs. The finding that the percentage of GFP+ LSK cells
increases upon in vivo selection suggests that the increased GFP
marking in PBMCs is not only due to cell cycle changes in HSCs
but also due to a selection advantage.
Others and our group previously reported that GFP-specific T cells
can develop in HSC gene therapy setting.1,21 This could be a third
element that contributes to low GFP marking in the periphery
without in vivo selection. Notably, immune-responses against a
therapeutic transgene product are absent when the transgene is
from the same species. MGMT is a human protein and it is expected
that there is also tolerance to the MGMTP140K mutant in humans.17
Our studies were performed in an adequate mouse model
(hCD46tg mice) that expressed the HDAd5/35++ receptor CD46
in a pattern and at a level similar to humans.22 We previously
showed that hCD46 in these mice is expressed on all bone marrow
HSCs.1 Notably, to bridge our studies in hCD46tg mice and poten-
tial studies in humans, we did not plan to use humanized mice
generated by sublethal irradiation of immunodeficient NSG mice
and transplantation of human CD34+ cells. These mice have
abnormal bone marrow structure, hematopoiesis, and are difficult
to mobilize.23 To translate our approach into the clinic, we will
focus on efficacy studies on mouse models for human diseases
(e.g., b-thalassemia or Fanconi anemia) and safety studies in
non-human primates. Importantly, we have used the mgmt-based
in vivo HSC selection approach using temozolomide (in the context
of lentivirus vectors) in patients with glioblastoma.15,24 Further-
more, we have an ongoing clinical study using it to increase HIV& Clinical Development Vol. 8 March 2018 61
Molecular Therapy: Methods & Clinical Developmentresistant cells in vivo. Therefore, this approach is clearly feasible and
thus highly relevant for hemoglobinopathies.
In none of the long-term follow-up studies involving ex vivo lenti-
virus vector-transduced HSCs and mgtm-based in vivo selection in
dogs or non-human primates, clonal dominance or leukemic events
have been found.11,14 The SB100x transposase system confers
random transgene integration into the genome of HSCs.1 From a
genotoxicity standpoint, this is, theoretically better than currently
used lentivirus or rAAV vectors, which have preference for inte-
grating into active genes. To address concerns of potential activation
of proto-oncogenes with our in vivo HSC transduction/selection
approach, we are planning longitudinal integration site studies in
non-human primates.
In summary, our in vivo HSC transduction/selection is well tolerated
and capable of achieving high transgene marking levels in peripheral
blood cells. Importantly, our approach eliminates the need for HSC
isolation, in vitro culture and transplantation and should therefore
make HSC gene therapy more accessible to patients.MATERIALS AND METHODS
Reagents
G-CSF (Neupogen) fom Amgen (Thousand Oaks, CA, USA),
AMD3100 from Sigma-Aldrich (St. Louis, MO, USA), BIO5192
from Tocris (Bristol, UK), and heparin from Fresenius Kabi (Lake
Zurich, IL, USA) were used. BOP was provided by CSIRO (Clayton,
VIC, Australia). O6-BG and BCNU were from Sigma-Aldrich
(St, Louis, MO, USA).HDAd Vectors
Stable transduction studies were performed with helper-dependent
HDAd5/35++ vectors using a hyperactive Sleeping Beauty transpo-
sase (SB100x) system for integration of the GFP transgene cassette.3,25
This vector systems consists of two vectors. The transposon vector
(HDAd-GFP) carries a GFP expression cassette that is flanked by
inverted transposon repeats (IR) and frt sites. The second vector
(HDAd-SB) provides both Flpe recombinase and SB100x transposase
in trans.1 The HDAd-GFP/mgmt vector was constructed as follows:
the EF1a-mgmt(P140K)-2a-GFP-pA was synthesized by Genscript
(Nanjing, China). The cassette was released by ICeu-I, blunted, and
inserted into the Pme I site of pHM5-FIP between the two Sleeping
Beauty IRs. The complete transposon cassette was then released by
PI-SceI and I-CeuI digest and introduced into pHCA via recombin-
eering.26 For the production of HDAd-SB and HDAd-mgmt/GFP
virus, corresponding plasmids were linearized with PmeI and rescued
in 116 cells27 with AdNG163-5/35++, an Ad5/35++ helper vector
containing chimeric fibers composed of the Ad5 fiber tail, the Ad35
fiber shaft, and the affinity-enhanced Ad35++ fiber knob.1 Helper
virus contamination levels were found to be <0.05%. All preparations
were free of bacterial endotoxin. Titers were 3 to 9  1012 viral
particles (vp)/mL.62 Molecular Therapy: Methods & Clinical Development Vol. 8 March 2Mobilization and In Vivo Transduction
All experiments involving animals were conducted in accordance
with the institutional guidelines set forth by the University of
Washington. The University of Washington is an Association for
the Assessment and Accreditation of Laboratory Animal Care Inter-
national (AALAC)-accredited research institution, and all live animal
work conducted at this university is in accordance with the Office of
Laboratory AnimalWelfare (OLAW) Public Health Assurance (PHS)
policy, USDA Animal Welfare Act and Regulations, the Guide for
the Care and Use of Laboratory Animals, and the University of
Washington’s Institutional Animal Care and Use Committee
(IACUC) policies. The studies were approved by the University of
Washington IACUC (Protocol No. 3108-01.
HSCs were mobilized in mice by subcutaneous (s.c.) injection of
human recombinant G-CSF (5 mg/mouse/day, 4 days) followed by
an s.c. injection of AMD3100 (5mg/kg) on day 5. In addition, animals
received dexamethasone (10 mg/kg) i.p. 16 and 2 hr before virus
injection. 30 and 60 min after AMD3100, animals were intravenously
injected with a 1:1 mixture of HDAd-mgtm/GFP and HDAd-SB
through the retro-orbital plexus with a dose of 4  1010 vp per
injection (animals in Figures 1, 5, and 6). The animals in Figures 3
and 7 received 2  1010 vp per injection.
In Vivo Selection
hCD46tg mice were mobilized and intravenously (i.v.) injected with
HDAd-mgtm/GFP + HDAd-SB. 4 weeks later, O6-BG/BCNU treat-
ment was started. Mice were injected with O6-BG (15 mg/kg,
intraperitoneal [IP]) 2 times, 30 min apart. 1 hr after the second
injection of O6-BG, mice were injected with BCNU (2.5 mg/kg, IP).
The BCNU dose was increased in the second and third cycles
to 7.5 and 10 mg/kg, respectively.
qPCR for Ad Genomes
Genomic DNA (gDNA) was isolated using the Blood and Tissue
Kit (QIAGEN, Valencia, CA, USA) in accordance with the manufac-
turer’s instructions, and gDNA concentration was determined
spectrophotometrically. gDNA samples were analyzed for vector
genomes carrying a GFP cassette with the following primers:
FWD: TCGTGACCACCCTGACCTAC, REV: GGTCTTGTAGTT
GCCGTCGT. qPCR was performed using the Kapa SYBR Fast
qPCR Kit Master Mix (Kapa Biosystems, Boston, MA, USA). Each
reaction was run in triplicates. Serial dilutions of purified HDAd-GFP
viral DNA were used as a standard curve.
Flow Cytometry
Cells were resuspended at 1  106 cells/100 mL in PBS supple-
mented with 1% fetal calf serum (FCS) and incubated with Fc recep-
tor (FcR) blocking reagent (Miltenyi Biotech, Auburn, CA, USA) for
10 min on ice. Next, the staining antibody solution was added in
100 mL per 106 cells and incubated on ice for 30 min in the dark.
After incubation cells were washed once in fluorescence-activated
cell sorting (FACS) buffer. For secondary staining, the staining
step was repeated with a secondary staining solution. After the018
www.moleculartherapy.orgwash, cells were resuspended in FACS buffer and analyzed using a
LSRII flow cytometer (BD Biosciences). Debris was excluded using a
forward scatter-area and sideward scatter-area gate. Single cells were
then gated using a forward scatter-height and forward scatter-width
gate. Flow cytometry data were then analyzed using FlowJo
(v.10.0.8).
The following flow cytometry antibodies and reagents were used:
lineage cell detection cocktail-biotin (mouse; Miltenyi Biotec); strep-
tavidin allophycocyanin (APC; eBioscience, San Diego, CA, USA);
anti-mouse LY-6A/E (Sca-1), PE-Cyanine7, clone D7 (eBioscience);
anti-mouse CD117 (c-Kit)-PE, Clone 2B8 (eBioscience); anti-
Mouse CD3 APC, Clone 17A2 (eBioscience); anti-mouse CD19-
PE-Cyanine7, Clone eBio1D3 (eBioscience); anti-mouse Ly-66
(Gr-1)-PE, Clone RB6-8C5 (eBioscience); and anti-mouse TER-
119-APC, Clone TER-119 (Biolegend, San Diego, CA, USA).
Magnetic Cell Sorting
For the depletion of lineage-committed cells, the Mouse Lineage Cell
Depletion Kit (Miltenyi Biotec, San Diego, CA, USA) was used in
accordance with the manufacturer’s instructions.
CFU Assay
1,500 lineage, GFP+ cells were plated in triplicates in ColonyGEL
1202 mouse complete medium (ReachBio, Seattle, WA, USA) and
incubated for 12 days at 37C in 5% CO2 and maximum humidity.
Colonies were enumerated using a Leica MS 5 dissection microscope
(Leica Microsystems). For scoring of GFP+ colonies, an Olympus
IMT-2 UV microscope was used with a DFC 300 FX camera (Leica
Microsystems).
Tissue GFP Immunofluorescence Analysis
Before tissue harvest, blood was flushed from the circulation with
PBS using the heart as a pump. Tissues were fixed in formalin over-
night (o/n) and subsequently incubated for 2 hr in PBS and 5%,
10%, and 20% sucrose. Tissues were then embedded in optimal
cutting temperature compound (OCT) and sectioned (6 mm).
Sections were incubated with Vectashield containing DAPI (Vector
Laboratories, Burlingame, CA, USA). Immunofluorescence micro-
photographs were taken at room temperature on a Leica DMLB
microscope (Leica, Wetzlar, Germany), with a Leica DFC300FX
digital camera and Leica Application Suite (v.2.4.1) R1 (Leica
Microsystems, Heerbrugg, Switzerland). No specific feature within
images shown in was enhanced, obscured, moved, removed, or
introduced.
Secondary Bone Marrow Transplantation
Recipients were 6- to 8-week-old female C57BL/6 mice. On the day
of transplantation, recipient mice were irradiated with 1000 Rad.
Bone marrow cells from in vivo-transduced hCD46tg mice were
isolated aseptically, and lineage-depleted cells were isolated
using magnetic cell sorting (MACS). 4 hr after irradiation, cells
were injected intravenously through the tail vein at 1  106 cells
per mouse.MolecuBlood Cell Counts
Blood samples were collected into EDTA-coated tubes, and analysis
was performed on a HemaVet 950FS machine (Drew Scientific,
Waterbury, CT, USA)
Statistical Analyses
For comparisons of multiple groups, one-way and two-way analysis
of variance (ANOVA) with Bonferroni post-testing for multiple com-
parisons was employed. Statistical analysis was performed using
GraphPad Prism (v.6.01) (GraphPad Software, La Jolla, CA, USA).
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